Top Markets
#1 Prom Prom +31.47%
#2 QuantixAI QuantixAI +31.15%
#3 Velvet Velvet +29.00%
#4 MowCat MowCat +28.48%
#5 Tutorial Tutorial +25.72%
#6 UnifAI Network UnifAI Network +24.16%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +21.78%
#8 MarsCoin MarsCoin +18.70%
#9 Versatize Coin Versatize Coin +16.65%
#10 GEKKO GEKKO +13.99%
Coin of the day
Prom Prom
Settings
Language
ENGLISH
Currency
USD
Theme
Bioceltix S.a. Bioceltix S.a.

Bioceltix S.a.

BCX
Rank in Stocks #20720
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals... Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Share Price
$22.35
Market Cap
$123.66M
Change (1 day)
-0.75%
Change (1 year)
-22.53%
Country
PL
Trade Bioceltix S.a. (BCX)

Category

Healthcare
Revenue for Bioceltix S.a. (BCX)
Revenue in Aug 2026 TTM: 0
According to Bioceltix S.a. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Bioceltix S.a. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH